Interaction analysis of the new pooled cohort equations for 10-year atherosclerotic cardiovascular disease risk estimation: a simulation analysis

Schiros, Chun G.; Denney Jr, Thomas S.; Gupta, Himanshu
April 2015
BMJ Open;Apr2015, Vol. 5 Issue 4, p1
Academic Journal
No abstract available.


Related Articles

  • Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting. Yook Chin Chia; Hooi Min Lim; Siew Mooi Ching // BMC Family Practice;2014, Vol. 15 Issue 1, p172 

    Background: Initiation of statin therapy as primary prevention particularly in those with mildly elevated cardiovascular disease risk factors is still being debated. The 2013 ACC/AHA blood cholesterol guideline recommends initiation of statin by estimating the 10-year atherosclerotic...

  • ACC/AHA Pooled Cohort Risk Equations predicted 5-y risk for CV events in adults considered for statin initiation. Navar-Boggan, Ann Marie; Newby, L. Kristin // ACP Journal Club;8/1/2014, Vol. 161 Issue 4, p1 

    The article focuses on a study that aims to find out whether American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Equations predict risk for atherosclerotic cardiovascular disease (ASCVD) in community-dwelling adults considered for statin, a drug, initiation. It...

  • New risk-prediction guideline: Headed in the right direction, but limitations persist. Michos, Erin D. // Cardiology Today;Feb2014, Vol. 17 Issue 2, p6 

    The author comments on the 2013 American College of Cardiology/American Heart Association Guideline on the Assessment of Cardiovascular Risk which now includes a new 10-year risk score for estimating hard atherosclerotic cardiovascular disease (ASCVD) and separate risk equations for sex and...

  • Cardiovascular highlights from non-cardiology journals. Bradley, Steven M. // Heart;Aug2014, Vol. 100 Issue 15, p1218 

    The article offers information on research related to cardiovascular diseases (CVDs) that have been published in different non-cardiology periodicals. Topics discussed include development of the atherosclerotic CVD risk prediction tool Pooled Cohort risk equation, statin therapy for patients...

  • Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular Disease: Grand Rounds Discussion From the Beth Israel Deaconess Medical Center. Mittleman, Murray A.; Taylor, William C.; Smetana, Gerald; Burns, Risa B. // Annals of Internal Medicine;8/18/2015, Vol. 163 Issue 4, p280 

    In November 2013, the American College of Cardiology and the American Heart Association released a clinical practice guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults. The recommendation identifies 4 patient groups with strong...

  • Validation of the pooled cohort risk score in an Asian population - a retrospective cohort study. Yook Chin Chia; Hooi Min Lim; Siew Mooi Ching // BMC Cardiovascular Disorders;2014, Vol. 14 Issue 1, p1 

    Background The Pooled Cohort Risk Equation was introduced by the American College of Cardiology (ACC) and American Heart Association (AHA) 2013 in their Blood Cholesterol Guideline to estimate the 10-year atherosclerotic cardiovascular disease (ASCVD) risk. However, absence of Asian ethnicity in...

  • Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations. Muntner, Paul; Colantonio, Lisandro D.; Cushman, Mary; Goff Jr, David C.; Howard, George; Howard, Virginia J.; Kissela, Brett; Levitan, Emily B.; Lloyd-Jones, Donald M.; Safford, Monika M. // JAMA: Journal of the American Medical Association;4/9/2014, Vol. 311 Issue 14, p1406 

    IMPORTANCE The American College of Cardiology/American Heart Association (ACC/AHA) Pooled Cohort risk equations were developed to estimate atherosclerotic cardiovascular disease (CVD) risk and guide statin initiation. OBJECTIVE To assess calibration and discrimination of the Pooled Cohort risk...

  • Factors Associated with Glycemic Variability in Patients with Type 2 Diabetes: Focus on Oral Hypoglycemic Agents and Cardiovascular Risk Factors. Soyeon Yoo; Sang-Ouk Chin; Sang-Ah Lee; Gwanpyo Koh // Endocrinology & Metabolism;Sep2015, Vol. 30 Issue 3, p352 

    Background: The role of glycemic variability (GV) in development of cardiovascular diseases remains controversial, and factors that determine glucose fluctuation in patients with diabetes are unknown. We investigated relationships between GV indices, kinds of oral hypoglycemic agents (OHAs), and...

  • Data Support New Cholesterol Treatment Guidelines. Greb, Erik // Neurology Reviews;May2014, Vol. 22 Issue 5, p1 

    The article discusses the development of the cohort risk equations for estimating the risk of atherosclerotic cardiovascular disease (ACVD) by the American College of Cardiology and the American Heart Association. Topics discussed include assessment of risk equation performance by using Reasons...

  • Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. Tangri, Navdeep; Grams, Morgan E.; Levey, Andrew S.; Coresh, Josef; Appel, Lawrence J.; Astor, Brad C.; Chodick, Gabriel; Collins, Allan J.; Djurdjev, Ognjenka; Elley, C. Raina; Evans, Marie; Garg, Amit X.; Hallan, Stein I.; Inker, Lesley A.; Sadayoshi Ito; Sun Ha Jee; Kovesdy, Csaba P.; Kronenberg, Florian; Heerspink, Hiddo J. Lambers; Marks, Angharad // JAMA: Journal of the American Medical Association;1/12/2016, Vol. 315 Issue 2, p164 

    Importance: Identifying patients at risk of chronic kidney disease (CKD) progression may facilitate more optimal nephrology care. Kidney failure risk equations, including such factors as age, sex, estimated glomerular filtration rate, and calcium and phosphate concentrations, were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics